90 related articles for article (PubMed ID: 16796526)
1. The N-terminal SRCR-SID domain of gp-340 interacts with HIV type 1 gp120 sequences and inhibits viral infection.
Wu Z; Lee S; Abrams W; Weissman D; Malamud D
AIDS Res Hum Retroviruses; 2006 Jun; 22(6):508-15. PubMed ID: 16796526
[TBL] [Abstract][Full Text] [Related]
2. gp340 (SAG) binds to the V3 sequence of gp120 important for chemokine receptor interaction.
Wu Z; Golub E; Abrams WR; Malamud D
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):600-7. PubMed ID: 15242536
[TBL] [Abstract][Full Text] [Related]
3. Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120.
Wu Z; Van Ryk D; Davis C; Abrams WR; Chaiken I; Magnani J; Malamud D
AIDS Res Hum Retroviruses; 2003 Mar; 19(3):201-9. PubMed ID: 12689412
[TBL] [Abstract][Full Text] [Related]
4. Binding of salivary agglutinin to IgA.
Ligtenberg AJ; Bikker FJ; De Blieck-Hogervorst JM; Veerman EC; Nieuw Amerongen AV
Biochem J; 2004 Oct; 383(Pt 1):159-64. PubMed ID: 15228387
[TBL] [Abstract][Full Text] [Related]
5. Cloning, expression and purification of the SRCR domains of glycoprotein 340.
Purushotham S; Deivanayagam C
Protein Expr Purif; 2013 Aug; 90(2):67-73. PubMed ID: 23707657
[TBL] [Abstract][Full Text] [Related]
6. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
[TBL] [Abstract][Full Text] [Related]
7. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
8. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.
Labrosse B; Treboute C; Brelot A; Alizon M
J Virol; 2001 Jun; 75(12):5457-64. PubMed ID: 11356952
[TBL] [Abstract][Full Text] [Related]
9. The putative sponge aggregation receptor. Isolation and characterization of a molecule composed of scavenger receptor cysteine-rich domains and short consensus repeats.
Blumbach B; Pancer Z; Diehl-Seifert B; Steffen R; Münkner J; Müller I; Müller WE
J Cell Sci; 1998 Sep; 111 ( Pt 17)():2635-44. PubMed ID: 9701562
[TBL] [Abstract][Full Text] [Related]
10. Identification of the bacteria-binding peptide domain on salivary agglutinin (gp-340/DMBT1), a member of the scavenger receptor cysteine-rich superfamily.
Bikker FJ; Ligtenberg AJ; Nazmi K; Veerman EC; van't Hof W; Bolscher JG; Poustka A; Nieuw Amerongen AV; Mollenhauer J
J Biol Chem; 2002 Aug; 277(35):32109-15. PubMed ID: 12050164
[TBL] [Abstract][Full Text] [Related]
11. Identification of human immunodeficiency virus type 1 (HIV-1) gp120-binding sites on scavenger receptor cysteine rich 1 (SRCR1) domain of gp340.
Chu Y; Li J; Wu X; Hua Z; Wu Z
J Biomed Sci; 2013 Jul; 20(1):44. PubMed ID: 23815775
[TBL] [Abstract][Full Text] [Related]
12. An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro.
Vu JR; Fouts T; Bobb K; Burns J; McDermott B; Israel DI; Godfrey K; DeVico A
AIDS Res Hum Retroviruses; 2006 Jun; 22(6):477-90. PubMed ID: 16796521
[TBL] [Abstract][Full Text] [Related]
13. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
14. Deleted in malignant brain tumors-1 protein (DMBT1): a pattern recognition receptor with multiple binding sites.
Ligtenberg AJ; Karlsson NG; Veerman EC
Int J Mol Sci; 2010; 11(12):5212-33. PubMed ID: 21614203
[TBL] [Abstract][Full Text] [Related]
15. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention.
Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J
Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512
[TBL] [Abstract][Full Text] [Related]
16. Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.
Savarino A; Bensi T; Chiocchetti A; Bottarel F; Mesturini R; Ferrero E; Calosso L; Deaglio S; Ortolan E; Buttò S; Cafaro A; Katada T; Ensoli B; Malavasi F; Dianzani U
FASEB J; 2003 Mar; 17(3):461-3. PubMed ID: 12551845
[TBL] [Abstract][Full Text] [Related]
17. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120.
Chiba H; Inokoshi J; Nakashima H; Omura S; Tanaka H
Biochem Biophys Res Commun; 2004 Mar; 316(1):203-10. PubMed ID: 15003531
[TBL] [Abstract][Full Text] [Related]
18. The N-terminal of the V3 loop in HIV type 1 gp120 is responsible for its conformation-dependent interaction with cell surface molecules.
Ling H; Usami O; Xiao P; Gu HX; Hattori T
AIDS Res Hum Retroviruses; 2004 Feb; 20(2):213-8. PubMed ID: 15018709
[TBL] [Abstract][Full Text] [Related]
19. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
[TBL] [Abstract][Full Text] [Related]
20. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
